AbbVie (ABBV) Stock: Price, Trend, Options & Financials
AbbVie's price regime, relative strength, unusual-options history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
ABBV closed at $271.36 on Oct 7, 2026. The price is +5.0% from its 50-day average and +16.9% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +8.6%, beating SPY by 5.2%. It remains 1.3% below its 52-week high.
Sources, methodology & freshnessSplit-adjusted OHLCV, end-of-day options chains, SEC 13F filings and EDGAR XBRL company facts · Price/options daily; 13F quarterly; Financials each earnings seasonData as of 2026-10-07 · Open ↓Close ↑
The close is +5.0% from its 50-day average and +16.9% from its 200-day average. Over three months, ABBV returned +8.6% versus +3.4% for SPY.
- vs 50-day
- +5.0%
- vs 200-day
- +16.9%
- From 52W high
- -1.3%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
ABBV appeared in a UOA top-30 list on 4 of 93 archived scanner sessions: 4 call-side, 0 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was 0.00, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-08-07 | #15 | — |
| 2026-06-15 | #13 | — |
| 2026-06-09 | #17 | — |
| 2026-05-26 | #26 | — |
Latest chain snapshot
2026-10-06Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.057 calls, 0.052 puts.
Curated-manager ownership
None of the 20 managers in the project's curated 13F set reported a long AbbVie position in their latest filing. That is an explicit absence within this focused panel, not evidence that the company has no institutional holders.
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open ABBV Financials →How ABBV trades — the working manual
AbbVie is a biopharmaceutical company spanning immunology, oncology, neuroscience and aesthetics. For the stock, the central question is whether newer medicines and acquired franchises can replace mature-product erosion while preserving margins and funding the research, business development and debt reduction needed for the next cycle.
What can move the tape
- 01Prescription growth, market share and indication expansion for the immunology portfolio.
- 02Revenue durability in neuroscience, oncology and aesthetics franchises.
- 03Clinical readouts, regulatory decisions and the commercial ramp of pipeline medicines.
- 04Operating margin, cash generation, acquisition integration and debt reduction.
What can fool the read
- 01Loss of exclusivity and biosimilar competition can accelerate erosion in major products.
- 02Pipeline setbacks can leave a larger gap between mature franchises and future revenue.
- 03Drug-pricing policy and payer access can affect both volume and realized price.
- 04Acquisition assumptions can disappoint while leverage limits capital-allocation flexibility.
No ABBV flags in the committed 2026-04-01–2026-10-07 archive. That means no session cleared this project's anomaly threshold; it does not mean trading volume was literally constant.
Not published yet. The local archive has 1 reported ABBV events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-10-05 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-10-07 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-10-06 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-10-07 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-27 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-10-07 | JSON ↓ |
ABBV stock questions
Is ABBV stock in an uptrend?+
ABBV is classified in the “established uptrend” regime as of 2026-10-07: the close is +5.0% from its 50-day average and +16.9% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in ABBV mean?+
AbbVie's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the ABBV 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are ABBV's income statement and cash flow?+
The dedicated ABBV Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no ABBV earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.